Kyntra Bio CFO has 22 shares withheld for taxes

KYNTRA BIO’s CFO had a small number of shares withheld to cover taxes on RSU vesting, leaving him with 4,355 directly held shares.

Available on EDGAR 09/09/2026 - 08:42 PM EDT Accepted by SEC EDGAR 09/09/2026 - 08:41 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

KYNTRA BIO, INC. (KYNB) reported that Chief Financial Officer David DeLucia had 22 shares of common stock disposed of on September 6, 2026 as part of a tax-withholding disposition related to vesting restricted stock units. The shares were withheld by the issuer to satisfy a tax obligation, not sold in an open-market trade. Following this event, DeLucia holds 4,355 shares of KYNTRA BIO common stock directly, and no Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Tax Withholding: 22 shares

Tax Withholding 1 txn

Insider DeLucia David

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	22	$8.55	$188.10

Holdings After Transaction: Common Stock — 4,355 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Key Figures

Shares withheld for tax obligation: 22 shares Reference price per share: $8.55 per share Shares held after transaction: 4,355 shares +1 more

4 metrics

Shares withheld for tax obligation 22 shares Common stock withheld on September 6, 2026 to satisfy tax from RSU vesting

Reference price per share $8.55 per share Price applied to the 22 shares withheld for tax purposes

Shares held after transaction 4,355 shares Direct common stock holdings of CFO David DeLucia after the tax-withholding disposition

Transactions for tax liability payment 1 transaction Single Form 4 transaction coded as payment of tax liability by withholding shares

Key Terms

restricted stock units, tax obligation, withheld by the issuer, Rule 10b5-1 trading plan

4 terms

restricted stock units financial

"upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligation financial

"to satisfy a tax obligation realized by the reporting person"

withheld by the issuer financial

"Represents shares withheld by the issuer to satisfy a tax obligation"

Rule 10b5-1 trading plan regulatory

"no Rule 10b5-1 trading plan is reported for this transaction"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KYNB report for its Chief Financial Officer?

KYNTRA BIO, INC. reported that CFO David DeLucia had 22 shares of common stock withheld on September 6, 2026 to satisfy a tax obligation arising from vesting restricted stock units.

Was the KYNB insider transaction an open-market sale?

No. The 22 shares reported for KYNTRA BIO’s CFO were withheld by the issuer to pay a tax obligation from RSU vesting, rather than sold in an open-market transaction.

What price per share is associated with the KYNB CFO’s tax-withholding transaction?

The tax-withholding disposition for KYNTRA BIO’s CFO used a reference price of $8.55 per share for the 22 shares withheld on September 6, 2026.

How many KYNB shares does the CFO hold after this Form 4 transaction?

After the reported tax-withholding disposition, KYNTRA BIO’s CFO David DeLucia directly holds 4,355 shares of the company’s common stock.

Was the KYNB CFO’s transaction under a Rule 10b5-1 trading plan?

No. The filing for KYNTRA BIO, INC. indicates no Rule 10b5-1 trading plan was reported in connection with this tax-withholding transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeLucia David

(Last) (First) (Middle)

C/O KYNTRA BIO INC.

350 BAY STREET, SUITE 100 # 6009

(Street)

SAN FRANCISCO CALIFORNIA 94133

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/06/2026		F		22(1)	D	$8.55	4,355	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

	/s/ John Alden, Attorney-in-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)